Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL : vimarsana.com

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Related Keywords

United States , Miami , Florida , , National Comprehensive Cancer Network Guidelines , International Congress On Hematologic Malignancies , International Congress , Hematologic Malignancies ,